Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University0 个研究点目标入组 113 人开始时间: 2022年12月13日最近更新: 2024年8月19日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 113

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The regression analysis demonstrated a negative association between rituximab exposure status and SR but not with SARS-CoV-2-specific IgG levels. Nine-month rituximab-to-vaccination cut-off fulfilled our prespecified diagnostic performance (SR difference between groups [95%CI]: -2.6 [-23.3, 18.1], LR+: 2.6) and coincided with the repopulation of naive B lymphocytes in these patients.

研究设计

研究类型: Observational

入排标准

年龄范围: 18 Years 至 N/A (No limit)（—）
性别: All

入选标准

•1. Being participants of our previous prospective cohort study or the one conducted parallel to ours by rheumatologists in the same institution, which evaluated immunogenicity of various types of COVID-19 vaccines in patients with immune-mediated dermatologic diseases (TCTR20220317008)
•2. Subjects who received at least one course of rituximab using any protocols before vaccination were included as an exposed group.
•3. Rituximab-naive subjects were recruited as an unexposed group.
•*exposed and unexposed group were matched for age and sex.

排除标准

•1. Subjects received rituximab or were diagnosed with COVID-19 between the first dose vaccination to the vaccine's immunogenicity assessment date
•2. The vaccine's immunogenicity data were missing

研究者

发起方

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University

相似试验

终止

2 期

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia AHemophilia A

NCT00306670Georgetown University2

已完成

不适用

Prospective study on the effects of rituximab on synovial tissue of patients with rheumatoid arthritis.rheumatoid arthritis

NL-OMON19978Academic Medical Center/University of Amsterdam32

已完成

3 期

Rituximab in Auto-Immune Hemolytic AnemiaWarm Autoimmune Hemolytic Anemia

NCT01181154Assistance Publique - Hôpitaux de Paris32

已完成

1 期

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy VolunteersHealthy Volunteers

NCT05274087AbbVie30

招募中

2 期

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyAdvanced Hepatocellular Carcinoma

NCT06301399Tianjin Medical University Cancer Institute and Hospital20